Abstract:Heart failure is a complicated clinical syndrome, which has become one of the most prevalent causes of mortality globally [ 1 von Lueder T.G. Krum H. New medical therapies for heart failure. Nat. Rev. Cardiol. 2015; Crossref PubMed Scopus (39) Google Scholar , 2 Edelmann F. Epidemiology and prognosis of heart failure. Herz. 2015; 40: 176-184 Crossref PubMed Scopus (7) Google Scholar ]. A major risk factor for the development of heart failure is cardiac hypertrophy, which is the compensatory response of the heart to stress [ [3] Bisping E. Wakula P. Poteser M. Heinzel F.R. Targeting cardiac hypertrophy: toward a causal heart failure therapy. J. Cardiovasc. Pharmacol. 2014; 64: 293-305 Crossref PubMed Scopus (64) Google Scholar ]. Cardiac hypertrophy results from a complex signaling cascade which converges upon certain transcription factors and then activates nuclear cardiac fetal gene programs and ultimately leads to pathological cardiac hypertrophy [ [4] Kohli S. Ahuja S. Rani V. Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy. Curr. Cardiol. Rev. 2011; 7: 262-271 Crossref PubMed Scopus (52) Google Scholar ]. Among them, the Ca2+/calmodulin-dependent phosphatase calcineurin (CaN) is considered as a central prohypertrophic signaling effector. Activated CaN directly binds to and dephosphorylates its downstream the Nuclear Factor of Activated T cells (NFAT) in the cytoplasm, promoting its translocation to the nucleus where it participates in hypertrophic gene expression [ 5 Taigen T. De Windt L.J. Lim H.W. Molkentin J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 1196-1201 Crossref PubMed Scopus (261) Google Scholar , 6 Walther S. Awad S. Lonchyna V.A. Blatter L.A. NFAT transcription factor regulation by urocortin II in cardiac myocytes and heart failure. Am. J. Physiol. Heart Circ. Physiol. 2014; 306: H856-H866 Crossref PubMed Scopus (13) Google Scholar ]. Therefore, looking for the calcineurin inhibitors that attenuate cardiac hypertrophy might be of great diagnostic and therapeutic significance for heart failure patients.

NFATc4 and Myocardin Synergistically Up-Regulate the Expression of LTCC Α1c in ET-1-induced Cardiomyocyte Hypertrophy.

Transcriptional Upregulation of Calcineurin Aβ by Endothelin-1 is Partially Mediated by Calcium/calmodulin-Dependent Protein Kinase IIδ3 in Rat Cardiomyocytes

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Cooperative Binding of ETS2 and NFAT Link Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy

Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes.

Ca²⁺ Signal-Induced Cardiomyocyte Hypertrophy Through Activation of Myocardin.

Ca2+/calmodulin-dependent Kinase II and Calcineurin Play Critical Roles in Endothelin-1-induced Cardiomyocyte Hypertrophy.

Myocardin-Related Transcription Factor-A Induces Cardiomyocyte Hypertrophy

NFAT5-mediated CACNA1C Expression is Critical for Cardiac Electrophysiological Development and Maturation

COX-2 is Involved in ET-1-induced Hypertrophy of Neonatal Rat Cardiomyocytes: Role of NFATc3.

Mir-9 and NFATc3 Regulate Myocardin in Cardiac Hypertrophy

LIM and Cysteine-Rich Domains 1 Regulates Cardiac Hypertrophy by Targeting Calcineurin/Nuclear Factor of Activated T Cells Signaling

The Mechanism of ET-1 Induced Growth-Promoting Effect in Cardiac Myocytes

Nesfatin-1 Suppresses Cardiac L-type Ca2+ Channels Through Melanocortin Type 4 Receptor and the Novel Protein Kinase C Theta Isoform Pathway

Sp1-induced LncRNA CTBP1-AS2 is a Novel Regulator in Cardiomyocyte Hypertrophy by Interacting with FUS to Stabilize TLR4

NF-κB (p65) Negatively Regulates Myocardin-Induced Cardiomyocyte Hypertrophy Through Multiple Mechanisms

The Calcineurin-Myocyte Enhancer Factor 2c Pathway Mediates Cardiac Hypertrophy Induced by Endoplasmic Reticulum Stress in Neonatal Rat Cardiomyocytes

Effects of PPAR-α Activation on ET-1-induced Cardiomyocyte Hypertrophy and Regulation of NFATc4

Calcineurin Enhances MAPK Phosphatase-1 Expression and p38 MAPK Inactivation in Cardiac Myocytes

Role of Calcineurin in Angiotensin II-induced Cardiac Myocyte Hypertrophy of Rats.

Carabin: Endogenous Calcineurin Inhibitor, a Potential Diagnostic and Therapeutic Target for Cardiac Hypertrophy in Heart Failure